Stockscreener 앱 받기
392.10
0.24%
0.93
시간 외 거래:
392.10
전일 마감가:
$391.17
열려 있는:
$394.18
하루 거래량:
1.04M
Relative Volume:
0.94
시가총액:
$51.80B
수익:
$3.21B
순이익/손실:
$43.57M
주가수익비율:
1,630.35
EPS:
0.2405
순현금흐름:
$221.36M
1주 성능:
-3.06%
1개월 성능:
-14.86%
6개월 성능:
+27.01%
1년 성능:
+59.02%
1일 변동 폭
$389.00
$400.24
1주일 범위
$387.03
$414.22
52주 변동 폭
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-04 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-08-04 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Alnylam launching $250 million biomanufacturing expansion in Norton - The Boston Globe
Alnylam's $250M Norton facility upgrade aims to slash need for 20 plants down to 2 - The Business Journals
Alnylam to Invest $250M in U.S. Manufacturing Expansion for RNAi Therapeutics - citybiz
Alnylam (ALNY) Advances Norton Facility with $250M Investment - GuruFocus
Alnylam to invest $250 million in expanding RNA drug manufacturing By Investing.com - Investing.com South Africa
Alnylam Pharmaceuticals to Invest $250 Million on Enzymatic Ligation Manufacturing Platform - marketscreener.com
Alnylam to invest $250 million to add enzymatic ligation platform - marketscreener.com
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics - Business Wire
Sanders Morris Harris LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Announces Health Canada Approval of AMVUTTRA® (vutrisiran), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis - BioSpace
Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions - MSN
Alnylam announces Health Canada approval of Amvuttra® - marketscreener.com
Alnylam Pharmaceuticals (ALNY) Stock Price, Quote, News & History - Benzinga
Gene Therapy Market to Reach US$ 35.91 Billion by 2033 at 23.1% - openPR.com
Is Alnylam Entering A Corrective Phase After A Strong Run? - Sahm
Assessing Alnylam Pharmaceuticals’ (ALNY) Valuation After Its Inclusion in the Nasdaq 100 Index - Yahoo Finance
Is Alnylam (ALNY) Using Nasdaq 100 Inclusion To Quietly Redefine Its Capital Allocation Playbook? - simplywall.st
Alnylam Pharmaceuticals (ALNY) Rating Maintained, Price Target L - GuruFocus
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $351.00 by Analysts at Leerink Partners - MarketBeat
Alnylam, Seagate among six stocks added to Nasdaq-100 in annual rebalance - MSN
Peptidream reveals milestone in Alnylam collaboration - BioWorld MedTech
Liontrust Investment Partners LLP Cuts Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
NASDAQ adding Alnylam, Ferrovial, Insmed, Monolithic Power at open on 12/22 - MSN
Holocene Advisors LP Invests $194.62 Million in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
China Universal Asset Management Co. Ltd. Trims Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
A look at Alnylam Pharmaceuticals (ALNY) valuation after Nasdaq 100 inclusion and convertible notes repurchase - simplywall.st
Alnylam Pharmaceuticals: Challenges In The TTR Space And Few Late-Stage Catalysts Are A Concern - Seeking Alpha
Seagate, Alnylam among six companies set to join Nasdaq 100 - MSN
Alnylam (ALNY) and Seagate (STX) Join Nasdaq 100 Index - GuruFocus
Gilder Gagnon Howe & Co. LLC Sells 8,487 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Eventide Asset Management LLC Sells 40,548 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Bellevue Group AG - MarketBeat
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options - sharewise.com
Seagate, Alnylam Are Among Six Companies Set to Join Nasdaq 100 - Bloomberg.com
Annual Changes to the Nasdaq-100 Index® - GlobeNewswire Inc.
How Good Is Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), When It Comes To ROE? - Yahoo Finance
Is It Too Late to Consider Alnylam Pharmaceuticals After Its Huge 2025 Share Price Surge? - simplywall.st
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027 - BioSpace
Is Alnylam Pharmaceuticals Stock Built to Withstand More Downside? - Trefis
$73 Billion Non-Opioid Therapeutics Industry Assessment, - GlobeNewswire
$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players - Yahoo Finance
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $508.00 - MarketBeat
WINTON GROUP Ltd Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam (ALNY) Announces $34.4M Convertible Notes Repurchase - GuruFocus
Alnylam Pharmaceuticals stock price target raised by Stifel to $508 - Investing.com
ALNY: Stifel Raises Price Target to $508, Maintains Buy Rating | ALNY Stock News - GuruFocus
Alnylam to repurchase $34.4 million of convertible notes - Investing.com
Alnylam announces partial repurchase of 1.00% convertible senior notes due 2027 - marketscreener.com
Alnylam Pharma Announces Convertible Notes Buyback - TipRanks
Alnylam Announces Partial Repurchase Of 1.00% Convertible Senior Notes Due 2027 - TradingView — Track All Markets
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.25%
1.10%
자본화:
|
볼륨(24시간):